A5026795331- Hepatitis C virus research
- HIV/AIDS drug development and treatment
- Hepatitis B Virus Studies
- HIV Research and Treatment
- Liver Disease Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- HIV/AIDS Research and Interventions
- Chronic Lymphocytic Leukemia Research
- Biochemical and Molecular Research
- SARS-CoV-2 and COVID-19 Research
- Parasites and Host Interactions
- Insect Utilization and Effects
- COVID-19 Clinical Research Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Insect Pest Control Strategies
- HIV-related health complications and treatments
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Outbreaks Research
- Glycosylation and Glycoproteins Research
- Invertebrate Immune Response Mechanisms
- Cytomegalovirus and herpesvirus research
- Pharmacological Effects and Toxicity Studies
- Vibrio bacteria research studies
- vaccines and immunoinformatics approaches
- Research on Leishmaniasis Studies
Janssen (Belgium)
2015-2025
Johnson & Johnson (United States)
2025
Justus-Liebig-Universität Gießen
2003-2021
Stadtspital Waid
2020
University Hospital of Zurich
2020
University of Zurich
2020
Freie Universität Berlin
2018
Janssen (Switzerland)
2016
Institut de Biologie Moléculaire et Cellulaire
2015
North Manchester General Hospital
2013
Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response therapy peginterferon alfa plus ribavirin.
Background: The present primary analysis of AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS) compares the efficacy and safety once-daily darunavir/ritonavir (DRV/r) that lopinavir/ritonavir (LPV/r) in treatment-naive patients. Methods: Patients HIV-1 RNA at least 5000 copies/ml were stratified by CD4 cell count a phase III, open-label trial, randomized to receive DRV/r 800/100 mg qd or LPV/r 800/200 total daily dose (bid qd) plus fixed-dose tenofovir emtricitabine for...
The purpose of this study was to characterize the antiviral activity, cytotoxicity, and mechanism action TMC114, a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI). TMC114 exhibited potent anti-HIV activity with 50% effective concentration (EC50) 5 nM 90% 2.7 13 nM. no cytotoxicity at concentrations up 100 muM (selectivity index, >20,000). All viruses in panel 19 recombinant clinical isolates carrying multiple mutations demonstrating resistance an average five other...
Abstract Dengue is a major health threat and the number of symptomatic infections caused by four dengue serotypes estimated to be 96 million 1 with annually around 10,000 deaths 2 . However, no antiviral drugs are available for treatment or prophylaxis dengue. We recently described interaction between non-structural proteins NS3 NS4B as promising target development pan-serotype virus (DENV) inhibitors 3 Here we present JNJ-1802—a highly potent DENV inhibitor that blocks NS3–NS4B within viral...
The screening of known HIV-1 protease inhibitors against a panel multi-drug-resistant viruses revealed the potent activity TMC126 on drug-resistant mutants. In comparison to amprenavir, improved affinity is largely result one extra hydrogen bond backbone protein in P2 pocket. Modification substitution pattern phenylsulfonamide P2' substituent created an interesting SAR, with close analogue TMC114 being found have similar antiviral mutant and wild-type viruses. X-ray thermodynamic studies...
Abstract Potential impact of ω-3 fatty acids, as contained in fish oil, on immunological function has been suggested because observations reduced inflammatory diseases Greenland Inuit were published. A oil-based lipid emulsion recently approved for parenteral nutrition many countries. We investigated the influence a short infusion course (ω-3) vs conventional (ω-6) monocyte function. In randomized design, twelve healthy volunteers received or ω-6 48 h, with cross-over repetition after 3 mo....
Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 trials determine frequency and retention variants who did not achieve sustained virologic response (SVR).
The resistance profile of darunavir (TMC114) in treatment-experienced patients was explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose with low-dose ritonavir (darunavir/r, 600/100 mg bid, N = 458). Baseline fold change EC50 a strong predictor virological response 24. Preliminary phenotypic clinical cut-offs 10 40 were established. Virological to darunavir/r maintained presence baseline high number IAS-USA PI resistance-associated mutations (IAS-USA RAMS);...
ABSTRACT The prevalence of naturally occurring hepatitis C virus (HCV) variants that are less sensitive to direct-acting antiviral (DAA) inhibitors has not been fully characterized. We used population sequence analysis assess the frequency such in plasma samples from 3,447 DAA-naive patients with genotype 1 HCV. In general, HCV lower-level resistance (3- 25-fold increased 50% inhibitor concentration [IC 50 ]) telaprevir were observed as dominant species 0 3% patients, depending on specific...
ObjectivesGiven the high need and absence of specific antivirals for treatment COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives.MethodsPrezcobix/Rezolsta is a fixed-dose combination 800 mg HIV inhibitor darunavir (DRV) 150 cobicistat, CYP3A4 inhibitor, which indicated in with other antiretroviral agents infection. There currently no...
Background & AimsSimeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of chronic HCV infection. Baseline NS3 polymorphisms in all patients and emerging mutations who failed to achieve sustained virologic response (SVR) with simeprevir plus peginterferon/ribavirin (PR) Phase IIb/III studies are described.MethodsBaseline sequencing data were available 2007 genotype 1 (GT1)-infected patients. Post-baseline 197/245 simeprevir-treated did not SVR. In...
Objective: In POWER 1 and 2, darunavir (TMC114) with low-dose ritonavir (darunavir/r) demonstrated greater efficacy versus control protease inhibitors (PIs). To examine the safety of selected darunavir/r dose further, additional patients were analyzed. Methods: Treatment-experienced HIV-1-infected received at a 600/100 mg twice daily plus an optimized background regimen. The primary intent-to-treat analysis was proportion HIV-1 RNA reduction ≥1 log10 week 24. Results: Three hundred...
Background In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared PR alone. However, genotypic changes could be observed TVR-treated who did not achieve an SVR. Methods Population sequence analysis of the NS3•4A region was performed SVR TVR-based treatment. Results Resistant variants were after treatment a telaprevir-based regimen 12% treatment-naïve...
The hypothesis was tested that insect meal (IM) as protein source influences intermediary metabolism of growing pigs. To test this, 30 male, 5-week-old crossbred pigs were randomly assigned to 3 groups 10 each with similar body weights (BW) and fed isonitrogenous diets either without (CON) or 5% IM (IM5) 10% (IM10) from Tenebrio molitor L. for 4 weeks key metabolic tissues (liver, muscle, plasma) analyzed using omics-techniques. Most performance parameters did not differ across the groups,...
Long-term (96-week) efficacy and safety of the protease inhibitor (PI) darunavir coadministered with low-dose ritonavir (DRV/r) was evaluated in HIV type-1 (HIV-1)-infected patients extensive prior treatment experience POWER 1, 2 3 trials.Patients HIV-1 RNA>or=1,000 copies/ml >or=1 primary PI mutation were randomized to receive either DRV/r 600/100 mg twice daily plus an optimized background regimen (OBR), or investigator-selected control (CPI) OBR (POWER a single-arm study). The proportion...
Abstract Although vaccination campaigns are currently being rolled out to prevent coronavirus disease (COVID‐19), antivirals will remain an important adjunct vaccination. Antivirals against coronaviruses do not exist, hence global drug repurposing efforts have been carried identify agents that may provide clinical benefit patients with COVID‐19. Itraconazole, antifungal agent, has reported activity animal coronaviruses. Using cell‐based phenotypic assays, the in vitro antiviral of...
Characterization of resistance development in virologic failure patients on the protease inhibitor darunavir administered with low-dose ritonavir (DRV/r) 48-week analysis TMC114/r In Treatment-experienced pAtients Naive to lopinavir (TITAN).TITAN is a randomized, controlled, open-label, phase III, noninferiority trial comparing efficacy and safety DRV/r that lopinavir/ritonavir (LPV/r) HIV-1-infected, treatment-experienced, LPV-naive patients. The primary endpoint was proportion HIV-1 RNA...
Background & AimsWe performed an open-label, multicenter, phase 3 study of the safety and efficacy twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those cirrhosis.MethodsPatients were randomly assigned to groups treated 1125 mg twice daily or 750 every 8 hours plus peginterferon alfa-2a ribavirin for 12 weeks; then alone weeks if their level HCV RNA at week 4 was <25 IU/mL 36 higher. The primary objective demonstrate...